<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1361">
  <stage>Registered</stage>
  <submitdate>25/10/2004</submitdate>
  <approvaldate>25/10/2004</approvaldate>
  <actrnumber>ACTRN12606000290594</actrnumber>
  <trial_identification>
    <studytitle>Evaluation of lung lavage in meconium aspiration syndrome</studytitle>
    <scientifictitle>A randomised controlled trial of therapeutic lung lavage to reduce the duration of respiratory support required by ventilated newborn infants with meconium aspiration syndrome (MAS)</scientifictitle>
    <utrn />
    <trialacronym>lessMAS</trialacronym>
    <secondaryid>Perinatal Trials Registry: PTR535</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Meconium aspiration syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Complications of newborn</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Lung lavage with 30 ml/kg surfactant solution (5mgs/ml), administered in 2 aliquots, each lasting 1 minute (under 10 minutes for entire procedure), within 24 hours after birth.</interventions>
    <comparator>Standard care of the ventilated neonate with meconium aspiration syndrome</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Total duration of respiratory support (ventilation plus nasal continuous positive airway pressure) during initial hospitalisation</outcome>
      <timepoint>First hospitalisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Mortality</outcome>
      <timepoint>First hospitalisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of pneumothorax</outcome>
      <timepoint>First hospitalisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of oxygen therapy</outcome>
      <timepoint>First hospitalisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Intubation and hospitalisation</outcome>
      <timepoint>First hospitalisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Respiratory morbidity</outcome>
      <timepoint>In 1st year pf life.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Neurodevelopmental outcome</outcome>
      <timepoint>At 2 years.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Neonates (males and females)with confirmed diagnosis of meconium aspiration syndrome with all of the following:1. birth weight &gt;2.0kgs, gestation &gt;36 weeks.2. &lt;24 hours of age3. ventilated with mean airway pressure &gt;/= 12 cm H2O4. Alveolar-arterial oxygen difference &gt;/= 450 mmHg</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Days</inclusiveminagetype>
    <inclusivemaxage>1</inclusivemaxage>
    <inclusivemaxagetype>Days</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Known or suspected cardiac abnormality.  Severe hypoxic ischaemic encephalopathy or congenital anomaly (ie, withdrawal of treatment being considered). Intractable cardiorespiratory instability.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>Permuted block randomisation, variable block size; stratified allocation by study centre</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/03/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>66</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>A/Prof Peter Dargaville</primarysponsorname>
    <primarysponsoraddress>Royal Hobart Hospital
Liverpool St
Hobart
TAS 7000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health &amp; Medical Research Council</fundingname>
      <fundingaddress>Canberra</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Meconium aspiration syndrome (MAS) is a complex disease of the newborn lung that can cause life-threatening respiratory distress very soon after birth.  Current management consists mainly of providing supportive care, rather than removing meconium from the lung to hault or slow disease progression.  This multicentre randomised controlled trial will test whether therapeutic lung lavage, using a dilute surfactant preparation, improves outcomes in infants with severe MAS.  The study will include a total of 66 newborn infants, who are receiving mechanical ventilation because of MAS.  The main outcome measure will be duration of respiratory support; secondary outcomes will be duration of oxygen therpay; duration of hospitalisation, and evidence of chronic lung disease.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Children's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Women's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mercy Hospital fpr Women</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Women's and Children's Hospital Adelaide</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Hobart Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Hospital for Women</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane and Women's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Darwin Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Middlemore Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>National Women's Hospital Auckland</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Wellington Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>KK Women's and Children's Hospital Singapore</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Singapore</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Singapore General Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Singapore</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Ipoh Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Malaysia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>HUKM Kuala Lumpur</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Malaysia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Selayang Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Malaysia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Saitama Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Japan</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Taipei Veterans General Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Taiwan</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>A/Prof Peter Dargaville</name>
      <address>Royal Hobart Hospital
Liverpool St
Hobart 
TAS 7000</address>
      <phone>03 62227546</phone>
      <fax>03 62264864</fax>
      <email>lessmas.trial@rch.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Tanya O'Byrne</name>
      <address>Menzies Research Institute
Level 2, 199 Macquarie Street,
Hobart 
Tasmania 7000</address>
      <phone>03 62227886</phone>
      <fax>03 62264864</fax>
      <email>lessmas.trial@menzies.utas.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Peter Dargaville</name>
      <address>Royal Hobart Hospital
Liverpool St
Hobart 
TAS 7000</address>
      <phone>03 6222 7546</phone>
      <fax>03 6226 4864</fax>
      <email>peter.dargaville@dhhs.tas.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>